Bio-Rad Laboratories, Inc. (BIO) stock analysis
In our weekly check, Bio-Rad Laboratories, Inc. is graded C (A to F). Of 24 checks on debt, profit, cash flow and trend: 10 pass, warnings: 7, red flags: 7.
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. is a Healthcare company (Medical Devices) based in the United States, listed on NYSE as BIO.
What our checks show for BIO
Red flags
- The net margin fell by 106 points over 5 years, to 39.5%: the company keeps less of each sale as profit.
- The gross margin fell by 4.8 points, to 51.3%: costs are rising faster than prices.
- Operating cash flow is only 0.46x net profit: part of the reported profit does not arrive as cash.
- Analysts expect the net margin to shrink by 27.6 points from today's 39.5%.
- Revenue fell 2.6% a year over the last 3 years.
- The stock has fallen as much as 74% from a peak. Would you have held through that?
- Return on capital (ROCE) is only 1.2%.
Warning signs
- Operating profit covers interest only 3.2 times: a weak year could make the payments hard.
- Analysts expect earnings per share to shrink about 40.4% a year.
- Analysts expect only about 2.2% a year of growth in revenue.
- Earnings per share fell 32.1% a year over the last 3 years.
- The price swings a lot: 36.3% annual volatility. Expect large ups and downs.
- The stock is still below its previous peak.
- Thinly traded (about 255 thousand shares a day): buying and selling can move the price.
Strengths
- Net debt is only 0.6x a year of EBITDA: the balance sheet has room.
- The company keeps 39.5% of its revenue as net profit.
- Free cash flow is 12.7% of revenue: cash for dividends, buybacks or growth.
- The dividend takes 5% of profit: there is a cushion.
- The price is 9.6 times earnings (P/E), reasonable for its growth.
- The share count fell by 6.7% in 2 years: the company buys back its own shares.
Next earnings report: 2027-02-11
Similar companies
GMED · BRKR · PODD · ALGN · PEN · SNN
Questions
What grade does Bio-Rad Laboratories, Inc. (BIO) have?
In our weekly check, Bio-Rad Laboratories, Inc. is graded C (A to F). Of 24 checks on debt, profit, cash flow and trend: 10 pass, warnings: 7, red flags: 7. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of BIO stock?
This week's biggest flags for Bio-Rad Laboratories, Inc.: Margins falling, Gross margin falling, Profits not backed by cash. In total 14 of 24 checks show a warning or a red flag.
What does Bio-Rad Laboratories, Inc. do?
Bio-Rad Laboratories, Inc. is a Healthcare company (Medical Devices) based in the United States, listed on NYSE as BIO.
When does Bio-Rad Laboratories, Inc. report earnings next?
The next earnings report is expected on 2027-02-11. We re-run the checks every week, so the grade can change after it.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis